Do analysts prefer ONCO or SYBX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, ONCO or SYBX?

Onconetix has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Onconetix $810K 3.59 -$14.03M $248.12 0.00 Synlogic $8K 1,791.42 -$23.36M -$0.06 N/A

Is ONCO or SYBX more profitable?

Synlogic has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. Synlogic's return on equity of -26.47% beat Onconetix's return on equity. Company Net Margins Return on Equity Return on Assets Onconetix -1,575.89% -91.95% -53.76% Synlogic N/A -26.47% -18.00%

Do analysts prefer ONCO or PHIO?

Phio Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 1,300.00%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Onconetix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor ONCO or PHIO?

In the previous week, Onconetix had 5 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 9 mentions for Onconetix and 4 mentions for Phio Pharmaceuticals. Onconetix's average media sentiment score of 0.91 beat Phio Pharmaceuticals' score of 0.67 indicating that Onconetix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Onconetix 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phio Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend ONCO or AEON?

AEON Biopharma has a consensus target price of $1.33, indicating a potential upside of 418.81%. Given AEON Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe AEON Biopharma is more favorable than Onconetix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AEON Biopharma 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80

Does the media prefer ONCO or AEON?

In the previous week, Onconetix had 8 more articles in the media than AEON Biopharma. MarketBeat recorded 9 mentions for Onconetix and 1 mentions for AEON Biopharma. Onconetix's average media sentiment score of 0.91 beat AEON Biopharma's score of -0.47 indicating that Onconetix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Onconetix 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AEON Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer LNAI or ONCO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LNAI or ONCO more profitable?

Lunai Bioworks has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. Onconetix's return on equity of -91.95% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% Onconetix -1,575.89% -91.95% -53.76%

Does the media refer more to LNAI or ONCO?

In the previous week, Onconetix had 7 more articles in the media than Lunai Bioworks. MarketBeat recorded 9 mentions for Onconetix and 2 mentions for Lunai Bioworks. Lunai Bioworks' average media sentiment score of 0.93 beat Onconetix's score of 0.91 indicating that Lunai Bioworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lunai Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Onconetix 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer ONCO or FBLG?

FibroBiologics has a consensus target price of $73.00, indicating a potential upside of 5,004.90%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts clearly believe FibroBiologics is more favorable than Onconetix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 FibroBiologics 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80

Is ONCO or FBLG more profitable?

FibroBiologics has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. Onconetix's return on equity of -91.95% beat FibroBiologics' return on equity. Company Net Margins Return on Equity Return on Assets Onconetix -1,575.89% -91.95% -53.76% FibroBiologics N/A -536.78% -225.12%

Does the media refer more to ONCO or FBLG?

In the previous week, Onconetix had 5 more articles in the media than FibroBiologics. MarketBeat recorded 9 mentions for Onconetix and 4 mentions for FibroBiologics. Onconetix's average media sentiment score of 0.91 beat FibroBiologics' score of 0.62 indicating that Onconetix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Onconetix 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FibroBiologics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Onconetix (ONCO) Competitors

$0.66 +0.02 (+2.82%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$0.64 -0.02 (-2.77%)

As of 08:23 AM Eastern

Compare

ONCO vs. SYBX, PHIO, AEON, LNAI, and FBLG

Should you buy Onconetix stock or one of its competitors? Onconetix's main competitors and comparable companies include Synlogic (SYBX), Phio Pharmaceuticals (PHIO), AEON Biopharma (AEON), Lunai Bioworks (LNAI), and FibroBiologics (FBLG). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Onconetix compare to Synlogic?

Onconetix (NASDAQ:ONCO) and Synlogic (NASDAQ:SYBX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Synlogic has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. Synlogic's return on equity of -26.47% beat Onconetix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,575.89%	-91.95%	-53.76%
Synlogic	N/A	-26.47%	-18.00%

Onconetix has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$810K	3.59	-$14.03M	$248.12	0.00
Synlogic	$8K	1,791.42	-$23.36M	-$0.06	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

23.9% of Onconetix shares are held by institutional investors. Comparatively, 63.4% of Synlogic shares are held by institutional investors. 0.3% of Onconetix shares are held by company insiders. Comparatively, 2.6% of Synlogic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Onconetix had 9 more articles in the media than Synlogic. MarketBeat recorded 9 mentions for Onconetix and 0 mentions for Synlogic. Synlogic's average media sentiment score of 1.85 beat Onconetix's score of 0.91 indicating that Synlogic is being referred to more favorably in the news media.

Company	Overall Sentiment
Onconetix	Positive
Synlogic	Very Positive

Onconetix has a beta of 2.68, meaning that its stock price is 168% more volatile than the broader market. Comparatively, Synlogic has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market.

Summary

Synlogic beats Onconetix on 7 of the 13 factors compared between the two stocks.

How does Onconetix compare to Phio Pharmaceuticals?

Onconetix (NASDAQ:ONCO) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

In the previous week, Onconetix had 5 more articles in the media than Phio Pharmaceuticals. MarketBeat recorded 9 mentions for Onconetix and 4 mentions for Phio Pharmaceuticals. Onconetix's average media sentiment score of 0.91 beat Phio Pharmaceuticals' score of 0.67 indicating that Onconetix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Onconetix	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Phio Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Onconetix has a beta of 2.68, suggesting that its share price is 168% more volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market.

Phio Pharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 1,300.00%. Given Phio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Onconetix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Phio Pharmaceuticals has lower revenue, but higher earnings than Onconetix. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$810K	3.59	-$14.03M	$248.12	0.00
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A

Phio Pharmaceuticals has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. Phio Pharmaceuticals' return on equity of -87.41% beat Onconetix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,575.89%	-91.95%	-53.76%
Phio Pharmaceuticals	N/A	-87.41%	-79.76%

23.9% of Onconetix shares are owned by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 0.3% of Onconetix shares are owned by company insiders. Comparatively, 3.5% of Phio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Phio Pharmaceuticals beats Onconetix on 8 of the 15 factors compared between the two stocks.

How does Onconetix compare to AEON Biopharma?

Onconetix (NASDAQ:ONCO) and AEON Biopharma (NASDAQ:AEON) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Onconetix has a beta of 2.68, meaning that its stock price is 168% more volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

AEON Biopharma has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. AEON Biopharma's return on equity of 0.00% beat Onconetix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,575.89%	-91.95%	-53.76%
AEON Biopharma	N/A	N/A	-994.63%

Onconetix has higher revenue and earnings than AEON Biopharma. AEON Biopharma is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$810K	3.59	-$14.03M	$248.12	0.00
AEON Biopharma	N/A	N/A	-$36.63M	-$4.42	N/A

In the previous week, Onconetix had 8 more articles in the media than AEON Biopharma. MarketBeat recorded 9 mentions for Onconetix and 1 mentions for AEON Biopharma. Onconetix's average media sentiment score of 0.91 beat AEON Biopharma's score of -0.47 indicating that Onconetix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Onconetix	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AEON Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AEON Biopharma has a consensus target price of $1.33, indicating a potential upside of 418.81%. Given AEON Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe AEON Biopharma is more favorable than Onconetix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

23.9% of Onconetix shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 0.3% of Onconetix shares are owned by company insiders. Comparatively, 9.4% of AEON Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Onconetix beats AEON Biopharma on 8 of the 15 factors compared between the two stocks.

How does Onconetix compare to Lunai Bioworks?

Lunai Bioworks (NASDAQ:LNAI) and Onconetix (NASDAQ:ONCO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings, media sentiment and analyst recommendations.

71.4% of Lunai Bioworks shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by company insiders. Comparatively, 0.3% of Onconetix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Lunai Bioworks has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Onconetix has a beta of 2.68, indicating that its stock price is 168% more volatile than the broader market.

Lunai Bioworks has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. Onconetix's return on equity of -91.95% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
Onconetix	-1,575.89%	-91.95%	-53.76%

Onconetix has higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
Onconetix	$810K	3.59	-$14.03M	$248.12	0.00

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Onconetix had 7 more articles in the media than Lunai Bioworks. MarketBeat recorded 9 mentions for Onconetix and 2 mentions for Lunai Bioworks. Lunai Bioworks' average media sentiment score of 0.93 beat Onconetix's score of 0.91 indicating that Lunai Bioworks is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lunai Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Onconetix	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Onconetix beats Lunai Bioworks on 8 of the 12 factors compared between the two stocks.

How does Onconetix compare to FibroBiologics?

Onconetix (NASDAQ:ONCO) and FibroBiologics (NASDAQ:FBLG) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

FibroBiologics has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. Onconetix's return on equity of -91.95% beat FibroBiologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,575.89%	-91.95%	-53.76%
FibroBiologics	N/A	-536.78%	-225.12%

FibroBiologics has a consensus target price of $73.00, indicating a potential upside of 5,004.90%. Given FibroBiologics' stronger consensus rating and higher probable upside, analysts clearly believe FibroBiologics is more favorable than Onconetix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
FibroBiologics	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Onconetix had 5 more articles in the media than FibroBiologics. MarketBeat recorded 9 mentions for Onconetix and 4 mentions for FibroBiologics. Onconetix's average media sentiment score of 0.91 beat FibroBiologics' score of 0.62 indicating that Onconetix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Onconetix	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
FibroBiologics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Onconetix has a beta of 2.68, indicating that its share price is 168% more volatile than the broader market. Comparatively, FibroBiologics has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market.

23.9% of Onconetix shares are held by institutional investors. 0.3% of Onconetix shares are held by company insiders. Comparatively, 7.3% of FibroBiologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Onconetix has higher revenue and earnings than FibroBiologics. FibroBiologics is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$810K	3.59	-$14.03M	$248.12	0.00
FibroBiologics	N/A	N/A	-$18.65M	-$5.19	N/A

Summary

Onconetix beats FibroBiologics on 10 of the 15 factors compared between the two stocks.

Get Onconetix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONCO vs. The Competition

Export

Metric	Onconetix	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.83M	$3.84B	$7.22B	$14.93B
Dividend Yield	N/A	3.65%	2.57%	12.31%
P/E Ratio	0.00	14.33	273.84	25.33
Price / Sales	3.59	1,393.75	638.10	87.33
Price / Cash	N/A	108.06	76.40	50.90
Price / Book	0.00	15.13	10.32	6.24
Net Income	-$14.03M	-$22.78M	$3.49B	$358.55M
7 Day Performance	-15.19%	-2.54%	-0.84%	-1.20%
1 Month Performance	-12.42%	-2.87%	-1.37%	-4.26%
1 Year Performance	-99.58%	37.92%	21.12%	5.47%

Onconetix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONCO Onconetix	1.2938 of 5 stars	$0.66 +2.8%	N/A	-99.6%	$2.83M	$810K	0.00	12
SYBX Synlogic	0.2501 of 5 stars	$1.15 -2.1%	N/A	-32.8%	$14.09M	$8K	N/A	80	News Coverage
PHIO Phio Pharmaceuticals	4.4046 of 5 stars	$1.04 +1.0%	$14.00 +1,246.2%	-53.7%	$12.09M	N/A	N/A	10
AEON AEON Biopharma	4.1657 of 5 stars	$0.24 +3.0%	$1.33 +451.0%	-67.1%	$12.07M	N/A	1.34	5
LNAI Lunai Bioworks	0.3211 of 5 stars	$2.63 +1.3%	N/A	N/A	$11.85M	N/A	N/A	20	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONCO) was last updated on 9/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Onconetix (ONCO) Competitors

ONCO vs. SYBX, PHIO, AEON, LNAI, and FBLG

How does Onconetix compare to Synlogic?

Summary

How does Onconetix compare to Phio Pharmaceuticals?

Summary

How does Onconetix compare to AEON Biopharma?

Summary

How does Onconetix compare to Lunai Bioworks?

Summary

How does Onconetix compare to FibroBiologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCO vs. The Competition

Onconetix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Onconetix (ONCO) Competitors

ONCO vs. SYBX, PHIO, AEON, LNAI, and FBLG

How does Onconetix compare to Synlogic?

Is ONCO or SYBX more profitable?

Which has higher valuation and earnings, ONCO or SYBX?

Do analysts prefer ONCO or SYBX?

Do insiders & institutionals have more ownership in ONCO or SYBX?

Does the media favor ONCO or SYBX?

Which has more volatility and risk, ONCO or SYBX?

Summary

How does Onconetix compare to Phio Pharmaceuticals?

Does the media favor ONCO or PHIO?

Which has more risk & volatility, ONCO or PHIO?

Do analysts prefer ONCO or PHIO?

Which has higher earnings & valuation, ONCO or PHIO?

Is ONCO or PHIO more profitable?

Do institutionals and insiders hold more shares of ONCO or PHIO?

Summary

How does Onconetix compare to AEON Biopharma?

Which has more volatility & risk, ONCO or AEON?

Is ONCO or AEON more profitable?

Which has preferable earnings and valuation, ONCO or AEON?

Does the media prefer ONCO or AEON?

Do analysts recommend ONCO or AEON?

Do institutionals & insiders have more ownership in ONCO or AEON?

Summary

How does Onconetix compare to Lunai Bioworks?

Do institutionals and insiders hold more shares of LNAI or ONCO?

Which has more risk and volatility, LNAI or ONCO?

Is LNAI or ONCO more profitable?

Which has higher valuation and earnings, LNAI or ONCO?

Do analysts prefer LNAI or ONCO?

Does the media refer more to LNAI or ONCO?

Summary

How does Onconetix compare to FibroBiologics?

Is ONCO or FBLG more profitable?

Do analysts prefer ONCO or FBLG?

Does the media refer more to ONCO or FBLG?

Which has more risk & volatility, ONCO or FBLG?

Do insiders & institutionals have more ownership in ONCO or FBLG?

Which has stronger valuation and earnings, ONCO or FBLG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCO vs. The Competition

Onconetix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools